Tesamorelin cost: what egrifta and generic vials actually run

Last updated 2026-07-25

How much does tesamorelin actually cost?

There are really two separate price worlds here, and mixing them up is how people get confused or overpay. Brand-name Egrifta (tesamorelin for injection), the FDA-approved product, carries a list price that commonly lands in the $4,000 to $6,000+ per month range depending on dose and pharmacy, before any insurance adjustment or manufacturer savings program. Egrifta is approved specifically for reduction of excess visceral adipose tissue in HIV patients with lipodystrophy, and it was studied in that population in two pooled phase 3 placebo-controlled trials ^[1]. That narrow indication is also why insurance coverage is inconsistent outside of documented HIV-associated lipodystrophy. Compounded tesamorelin, made by a licensed 503A or 503B pharmacy from bulk peptide, is the option most people outside the HIV-lipodystrophy indication actually encounter. Pricing varies widely by pharmacy, dose, and vial size, but it's a fraction of brand pricing, often landing in the low hundreds of dollars per month rather than thousands. That price gap exists because compounded product skips brand R&D, marketing, and FDA's formal approval pathway. It does not mean the two products are interchangeable in quality or oversight, and buyers should treat 'cheap tesamorelin peptide for sale' listings with real skepticism about sourcing.

Why is brand-name Egrifta so expensive?

Egrifta's price reflects its status as a single-source, FDA-approved biologic-adjacent peptide drug with no generic competitor. It went through the full new drug approval process, including the pooled phase 3 trials that established its efficacy and safety in HIV-associated lipodystrophy ^[1][2]. That regulatory investment gets priced into every vial. There's also no therapeutic substitute carrying the same approval. Other GH-axis peptides and GHRH analogues exist in research and compounding contexts, but none carry an equivalent FDA approval for visceral fat reduction, so there's no generic-style price competition pushing the brand price down. Manufacturer savings cards and patient assistance programs can meaningfully cut what an insured or even uninsured patient pays out of pocket, but the underlying list price stays high. Anyone shopping strictly by sticker price should check with the manufacturer's own patient support program before assuming brand tesamorelin is unaffordable; for HIV patients with lipodystrophy, it may end up cheaper than expected after assistance.

Does insurance cover tesamorelin?

Coverage is realistic mainly for the approved indication: HIV-associated lipodystrophy with excess visceral fat, generally requiring physician documentation and sometimes imaging or waist circumference criteria consistent with the phase 3 trial entry criteria ^[1]. Even within that population, coverage varies by plan, and prior authorization is common. Outside that indication, meaning general visceral fat reduction, body composition goals, or anti-aging use, coverage is rare to nonexistent. Insurers generally don't pay for off-label use of an approved drug, and they have no coverage pathway at all for compounded, non-FDA-approved formulations. If cost is the deciding factor and you don't have HIV-associated lipodystrophy, expect to self-pay regardless of which product you use.

What's the real cost difference between Egrifta and compounded tesamorelin?

The gap is large enough that it shapes almost every purchasing decision in this space. Below is a rough comparison based on typical list pricing patterns and how compounding pharmacies commonly price monthly peptide supply; treat compounded figures as illustrative ranges since individual pharmacy pricing varies. | Product type | Regulatory status | Typical monthly cost | Insurance likelihood |

Is cheaper tesamorelin from research-chemical sellers worth the risk?

No, and this is the part of 'tesamorelin peptide for sale' shopping that deserves real caution. Peptides sold online labeled 'not for human consumption' or through generic research-chemical storefronts are not the same regulatory category as pharmacy-compounded product, let alone FDA-approved Egrifta. There's no chain of custody, no pharmacy oversight, and no guarantee the vial contains what the label says at the stated purity. The growth hormone-releasing hormone analogue class, which includes tesamorelin, is also a recognized target in anti-doping detection work, reflecting real-world circulation of unregulated GHRH analogues outside clinical channels ^[3]. That's not a reason to panic, but it is a signal that a gray market exists and that lab-grade labeling claims from unregulated sellers can't be taken at face value. If a price looks too good relative to compounding pharmacy quotes, that's the moment to ask who is actually manufacturing it, under what license, and whether there's any third-party purity testing behind the number on the page.

What drives the price difference between compounding pharmacies?

A few concrete variables move the number more than anything else. Vial size and concentration matter first: a pharmacy selling a multi-week supply at a higher concentration per vial changes the per-month math even if the sticker price on the vial looks similar to a competitor's. Second, 503A versus 503B status changes both price and oversight; 503B outsourcing facilities compound at larger scale under closer FDA manufacturing oversight (21 CFR 216.24) and sometimes charge differently than small 503A community pharmacies compounding patient-specific prescriptions under 21 U.S.C. 353a. Third, whether the pharmacy requires a prescription and clinician oversight versus operating as a direct-to-consumer research-use seller changes both legitimacy and price; skipping medical oversight is not actually a cost saving worth taking given the safety monitoring GHRH analogues warrant. Dosing frequency and cycle length also affect total spend, more than the per-vial price. A tesamorelin cycle length run over many months costs more in aggregate than a short protocol, so ask any provider for the expected total months of therapy, more than the monthly rate.

What does a typical monthly tesamorelin protocol cost to run?

For the approved use, standard Egrifta dosing in the original approval trials was a subcutaneous daily injection, and pricing quotes from pharmacies or manufacturers should be understood as a full month of daily dosing, not an occasional-use product ^[1][2]. That daily dosing schedule is exactly why the monthly price tag is what it is: this isn't a once-weekly injectable. For compounded protocols used off-label, total monthly cost depends on vial concentration, reconstitution volume, and how many mg per dose the prescribing clinician has set. Getting the reconstitution math wrong doesn't just waste product, it also skews your real cost per dose upward if you're drawing up more peptide than intended. If you're new to this, it's worth reading through how to reconstitute tesamorelin before assuming a vial will stretch as far as a seller's marketing suggests. Injection technique also affects whether you're getting consistent dosing out of each vial; see tesamorelin how to inject and tesamorelin injection sites for the practical side of not wasting product.

Are there hidden costs beyond the vial price?

Yes, several, and they add up. Supplies: needles, syringes, alcohol swabs, and sharps disposal aren't always included in a peptide's quoted price, and buying them separately at a pharmacy counter is a recurring small cost people forget to budget. Clinician visits and labs: legitimate use, whether for the approved HIV lipodystrophy indication or an off-label protocol under medical supervision, usually involves at least periodic follow-up, and possibly glucose or IGF-1 monitoring given tesamorelin's mechanism as a GHRH analogue that raises IGF-1 ^[4]. That's a real cost that a bare per-vial price doesn't capture. Wasted product from timing or storage mistakes: tesamorelin protocols are typically timed around specific windows relative to meals and sleep, and getting that wrong doesn't ruin a vial physically but can blunt the intended effect, making you feel like you're not getting value from what you paid for. The best time to take tesamorelin peptide page covers this in more detail.

Does tesamorelin actually work well enough to justify the cost?

Within its approved indication, yes, the trial evidence is real and specific. In the pooled phase 3 placebo-controlled trials in HIV patients with excess abdominal fat, tesamorelin reduced visceral adipose tissue relative to placebo, with the effect maintained through safety extension data ^[1]. A separate trial found visceral fat reduction with tesamorelin was associated with improved liver enzyme levels in HIV patients ^[5], and a randomized double-blind multicenter trial reported effects of tesamorelin on non-alcoholic fatty liver disease in HIV patients ^[6]. A more recent trial looked specifically at efficacy and safety of tesamorelin in people with HIV on integrase inhibitors ^[7], reflecting how HIV treatment regimens have evolved since the original approval studies. Outside the approved indication, meaning general fat loss or anti-aging use in people without HIV-associated lipodystrophy, there isn't a comparable trial base to point to. A 2026 meta-analysis of randomized controlled trials specifically evaluated body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin in HIV-associated lipodystrophy ^[8], again within that same population. If someone is paying compounding-pharmacy prices for tesamorelin hoping for the same visceral fat effect seen in HIV trials but without HIV-associated lipodystrophy, that's a real evidence gap worth knowing about before spending money, not after.

What should I check before I buy tesamorelin from any source?

A short, honest checklist, because this is where most people either save money safely or lose it. First, confirm whether you're buying an FDA-approved product (Egrifta) or a compounded formulation, and understand that these sit in genuinely different regulatory categories under 21 U.S.C. 353a and 21 CFR 216 [FDA 503A, FDA 503A list]. Second, if compounded, ask which pharmacy is doing the compounding, whether it's 503A or 503B, and whether tesamorelin (or its listed bulk substance) is currently permitted on FDA's bulk drug substance lists for that pathway; these lists change over time [FDA 503A list, FDA 503B list]. Third, require a prescription from a clinician who has actually reviewed your history, not a form filled out on a storefront checkout page. Fourth, ask about third-party testing on the specific batch, not a generic certificate template. Fifth, compare total monthly cost including supplies and any required monitoring, more than the advertised vial price. A provider-reviewed pathway, where a clinician evaluates you and a named pharmacy partner fulfills the prescription, is the more defensible route price-wise and safety-wise compared to a bare online peptide storefront. Tesamorelin Co's role in that pathway is connecting people to provider review; it does not compound or manufacture product itself, and the actual fulfillment sits with the pharmacy partner in that chain.

Why does tesamorelin cost more than some other peptides?

Part of it is molecular complexity and stability. Tesamorelin is a modified GHRH analogue, and GHRH-class peptides in general require careful synthesis and handling to remain stable, which is reflected in broader peptide chemistry literature on ligation and synthesis techniques for complex peptides ^[9]. That manufacturing complexity feeds into cost at the raw material level for any compounder, independent of brand markup. Part of it is also regulatory: as the only tesamorelin product with full FDA approval, Egrifta has no price pressure from an approved generic competitor, and that keeps brand pricing at the high end regardless of what raw peptide costs a compounding pharmacy pay for bulk material.

Frequently asked questions

How much does tesamorelin cost per month?

Brand-name Egrifta typically lists around $4,000 to $6,000+ per month before insurance or manufacturer savings programs. Compounded tesamorelin from a licensed pharmacy generally costs far less, often in the low hundreds of dollars monthly, though pricing varies significantly by pharmacy, dose, and vial concentration. Always get a specific quote rather than assuming either figure applies to your situation.

Why is Egrifta so expensive compared to compounded tesamorelin?

Egrifta is the only FDA-approved tesamorelin product, with regulatory and trial costs built into its price and no generic competitor to push pricing down. Compounded tesamorelin skips that approval pathway and is made under different pharmacy rules (21 U.S.C. 353a), which lowers cost but also means it lacks the same FDA-reviewed manufacturing standard.

Does insurance cover tesamorelin?

Coverage is realistic mainly for documented HIV-associated lipodystrophy, Egrifta's approved indication, and even then prior authorization is common. For off-label use in people without that diagnosis, or for any compounded formulation, insurance coverage is essentially nonexistent, since compounded products aren't FDA-approved finished drugs.

Can I buy tesamorelin peptide online cheaply and safely?

Buying from unregulated research-chemical sellers is risky: there's no pharmacy oversight, no verified chain of custody, and no guarantee of labeled purity. A provider-reviewed pathway using a licensed compounding pharmacy under a prescription is safer than a bare online storefront, even if the sticker price looks slightly higher.

Is compounded tesamorelin legal to buy?

It can be, under specific conditions. Section 503A (21 U.S.C. 353a) allows licensed pharmacies to compound patient-specific prescriptions, and FDA maintains bulk drug substance lists under 21 CFR 216.23 and 216.24 governing what can be compounded and under what pathway. Legality depends on the pharmacy's licensing and current bulk substance list status, which changes over time.

What is the FDA-approved use for tesamorelin, and does that affect price?

Egrifta is FDA-approved specifically to reduce excess visceral adipose tissue in HIV patients with lipodystrophy, based on pooled phase 3 placebo-controlled trials. That narrow approval is exactly why price is high (no generic competition) and why insurance coverage outside that specific population is rare.

Are manufacturer savings programs available for Egrifta?

Manufacturer patient assistance and savings card programs exist for many specialty drugs like Egrifta and can substantially cut out-of-pocket cost for eligible patients, particularly those with commercial insurance and a documented HIV-associated lipodystrophy diagnosis. Eligibility rules vary, so check directly with the manufacturer's program rather than assuming a fixed discount amount.

Does a higher price mean better quality tesamorelin?

Not necessarily, but a suspiciously low price relative to typical compounding pharmacy quotes is a real warning sign. Price alone doesn't verify purity or sourcing; what matters is whether the seller is a licensed 503A or 503B pharmacy operating under prescription, versus an unregulated online storefront with no pharmacy oversight.

What extra costs come with a tesamorelin protocol beyond the vial price?

Budget for needles, syringes, and sharps disposal, plus clinician visits and possible lab monitoring (glucose, IGF-1) given tesamorelin's mechanism as a GHRH analogue. These recurring costs aren't always included in a quoted vial price and can meaningfully change your real monthly spend.

Is tesamorelin worth the cost if I don't have HIV-associated lipodystrophy?

That's a genuine evidence gap. The strongest trial data on visceral fat reduction, liver enzyme improvement, and NAFLD outcomes comes specifically from HIV-associated lipodystrophy populations. Outside that group, there isn't a comparable randomized trial base, so paying for off-label use means accepting less certainty about the outcome you're paying for.

How does dosing frequency affect total tesamorelin cost?

Tesamorelin in the approval trials was dosed daily by subcutaneous injection, not weekly, so monthly cost reflects roughly 30 doses. Total cost over a full treatment course also depends on how many months the protocol runs, so ask about total expected duration, more than the price of one vial.

Where can I buy tesamorelin through a provider-reviewed pathway?

The safer route is clinician evaluation followed by prescription fulfillment through a licensed pharmacy partner, rather than direct purchase from an unregulated peptide storefront. Tesamorelin Co connects readers to provider review; the actual compounding and fulfillment is handled by the pharmacy partner in that chain, not by Tesamorelin Co itself.

Sources

1. Journal of Clinical Endocrinology and Metabolism, 2010 (PMID 20554713): Pooled analysis of two multicenter, double-blind, placebo-controlled phase 3 trials of tesamorelin in HIV patients with excess abdominal fat, including safety extension data.
2. Drugs, 2011 (PMID 21668043): Review of tesamorelin's use in the management of HIV-associated lipodystrophy.
3. Drug Testing and Analysis, 2021 (PMID 34665524): Advances in detection methods for GHRH synthetic analogs, reflecting monitoring of unregulated GHRH analogue circulation.
4. Nature Reviews Drug Discovery, 2011 (PMID 21283099): Tesamorelin's mechanism as a GHRH analogue and its effect on raising IGF-1 levels.
5. AIDS, 2017 (PMID 28832410): Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV patients.
6. The Lancet HIV, 2019 (PMID 31611038): Randomized, double-blind, multicenter trial of tesamorelin effects on non-alcoholic fatty liver disease in HIV.
7. AIDS, 2024 (PMID 38905488): Efficacy and safety of tesamorelin evaluated in people with HIV on integrase inhibitor regimens.
8. Obesity Research & Clinical Practice, 2026 (PMID 41545261): Meta-analysis of randomized controlled trials on body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin in HIV-associated lipodystrophy.
9. Journal of the American Chemical Society, 2020 (PMID 31840988): Peptide ligation chemistry techniques relevant to the manufacturing complexity of GHRH-class peptides like tesamorelin.
10. 21 U.S.C. 353a, pharmacy compounding (Cornell Law): Legal basis under which licensed pharmacies may compound drugs for individual patients under Section 503A.
11. 21 CFR 216.23, 503A Bulks List (eCFR): Federal regulation listing bulk drug substances permitted for 503A compounding.
12. 21 CFR 216.24, 503B Bulks List (eCFR): Federal regulation listing bulk drug substances permitted for 503B outsourcing facility compounding.
13. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: FDA guidance describing the framework and current status of bulk drug substances eligible for 503A compounding.